9,514 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Allstate Corp

Allstate Corp acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 9,514 shares of the company's stock, valued at approximately $396,000.

A number of other hedge funds have also modified their holdings of MRNA. Allworth Financial LP raised its holdings in shares of Moderna by 17.3% during the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after acquiring an additional 281 shares in the last quarter. Howard Capital Management Inc. increased its holdings in shares of Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after buying an additional 297 shares during the last quarter. Commonwealth Equity Services LLC raised its position in shares of Moderna by 0.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock valued at $3,099,000 after buying an additional 345 shares in the last quarter. Larson Financial Group LLC grew its position in Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock worth $53,000 after acquiring an additional 356 shares in the last quarter. Finally, New Insight Wealth Advisors grew its position in Moderna by 4.4% in the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company's stock worth $355,000 after acquiring an additional 358 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Royal Bank of Canada reissued a "sector perform" rating and issued a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. Morgan Stanley reduced their target price on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a report on Wednesday, January 15th. Evercore ISI set a $50.00 price target on shares of Moderna in a research note on Friday, February 14th. The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, Bank of America cut their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research note on Tuesday, February 11th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $59.00.

Remove Ads

Moderna Price Performance

Shares of MRNA traded down $0.62 during trading hours on Friday, hitting $25.11. 16,041,074 shares of the company were exchanged, compared to its average volume of 7,025,616. The firm has a fifty day simple moving average of $33.88 and a 200-day simple moving average of $43.31. The company has a market capitalization of $9.71 billion, a PE ratio of -2.71 and a beta of 2.23. Moderna, Inc. has a one year low of $23.79 and a one year high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.